These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 38182487)
1. Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients. Cussenot O; Timms KM; Perrot E; Blanchet P; Brureau L; Solimeno C; Fromont G; Comperat E; Cancel-Tassin G Eur Urol Oncol; 2024 Jun; 7(3):597-604. PubMed ID: 38182487 [TBL] [Abstract][Full Text] [Related]
2. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. Gandaglia G; Karakiewicz PI; Briganti A; Passoni NM; Schiffmann J; Trudeau V; Graefen M; Montorsi F; Sun M Eur Urol; 2015 Aug; 68(2):325-34. PubMed ID: 25108577 [TBL] [Abstract][Full Text] [Related]
3. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611 [TBL] [Abstract][Full Text] [Related]
4. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. Castro E; Goh C; Leongamornlert D; Saunders E; Tymrakiewicz M; Dadaev T; Govindasami K; Guy M; Ellis S; Frost D; Bancroft E; Cole T; Tischkowitz M; Kennedy MJ; Eason J; Brewer C; Evans DG; Davidson R; Eccles D; Porteous ME; Douglas F; Adlard J; Donaldson A; Antoniou AC; Kote-Jarai Z; Easton DF; Olmos D; Eeles R Eur Urol; 2015 Aug; 68(2):186-93. PubMed ID: 25454609 [TBL] [Abstract][Full Text] [Related]
5. An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer. Dawson NA; Zibelman M; Lindsay T; Feldman RA; Saul M; Gatalica Z; Korn WM; Heath EI Mol Cancer Ther; 2020 Jun; 19(6):1373-1382. PubMed ID: 32220973 [TBL] [Abstract][Full Text] [Related]
6. The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma. Karachaliou GS; Alkallas R; Carroll SB; Caressi C; Zakria D; Patel NM; Trembath DG; Ezzell JA; Pegna GJ; Googe PB; Galeotti JP; Ayvali F; Collichio FA; Lee CB; Ollila DW; Gulley ML; Johnson DB; Kim KB; Watson IR; Moschos SJ BMC Cancer; 2022 Jan; 22(1):38. PubMed ID: 34986841 [TBL] [Abstract][Full Text] [Related]
7. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer. Nizialek E; Lim SJ; Wang H; Isaacsson Velho P; Yegnasubramanian S; Antonarakis ES Prostate; 2021 Jun; 81(9):572-579. PubMed ID: 33955569 [TBL] [Abstract][Full Text] [Related]
8. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment. Arnold RS; Fedewa SA; Goodman M; Osunkoya AO; Kissick HT; Morrissey C; True LD; Petros JA Bone; 2015 Sep; 78():81-6. PubMed ID: 25952970 [TBL] [Abstract][Full Text] [Related]
9. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276 [TBL] [Abstract][Full Text] [Related]
10. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354 [TBL] [Abstract][Full Text] [Related]
11. Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients. Lai GS; Chen CS; Cheng JC; Li JR; Yang CK; Lin CY; Hung SC; Chiu KY; Wang SS PLoS One; 2024; 19(9):e0309941. PubMed ID: 39241021 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905 [TBL] [Abstract][Full Text] [Related]
13. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392 [TBL] [Abstract][Full Text] [Related]